Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Literature
1.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaboraters developing the Japanese equation for estimated GFR. Am J Kidney Dis. 2009;53(6):982–92.PubMedCrossRef
2.
Suzuki D, Takano H, Toyoda M, Umezono T, Uehara G, Sakai T, et al. Evaluation of renal biopsy samples of patients with diabetic nephropathy. Intern Med. 2001;40:1077–84.PubMedCrossRef
a. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–266.
b. Japanese Society of Nephrology. Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease. Nippon Jinzo Gakkai Shi. 2007;49:755–870.
c. De Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria:public health perspectives. J Am Soc Nephrol. 2006;17:2120–6.PubMedCrossRef
d. Japanese diabetic society, Japanese society of nephrology, Diabetic nephropathy committee. Revised criteria for the early diagnosis of diabetic nephropathy. J Japan Diab Soc. 2005;48:757–9.
e. Japanese Societies of Urology, Nephrology, Pediatric Nephrology, Clinical Laboratory Medicine, Clinical Health Laboratory Technician (Working Group for Hematuria Diagnosis Guideline). Hematuria Diagnosis Guideline, 2006.
f. Working Group for JCCLS Urine Dip Stick. Proposed Guideline by JCCLS: Methods for Urine Dip Stick. J Jpn Soc Norm Clin Exam. 2001;16:33–55.
g. JCCLS Working Groups for Normalization of Urinary Test and for Investigation of Urine Dip Stick. Proposed Guideline by JCCS (revised version): Unifying the Urinary Tests for Protein, Glucose and Occult Blood. J Jpn Soc Norm Clin Exam. 2004;19:53–65.
h. Aburano Y, Ito K. Current status and problems of urinary sediment test in Japan—correlation between red blood cells in urinary sediment and urinary occult blood reaction test. Nephrol Frontier. 2004;3:38–41.
j. Köhler H, Wandel E, Brunck B. Acanthocyturia—a characteristic marker for glomerular bleeding. Kidney Int. 1991;40:115–20.PubMedCrossRef
k. Guidebook of the renal biopsy. edited by the Japanese Society of Nephrology, Tokyo Igakusha Co., Ltd., Tokyo, 2004.
ℓ. Fuiano G, Mazza G, Comi N, Caqlioti A, DeNicola L, Iodice C, Andreucci M, Andreucci VE. Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis. 2000;35:448–57.PubMedCrossRef
m. Evidence-based practice guideline for the treatment of diabetes in Japan, 2nd ed., edited by the Japan Diabetes Society, Nankodo Co., Ltd., Tokyo, 2007.
n. American Diabetes Association. Nephropathy in Diabetes. Diabetes Care 2007;27:S79-83.
o. National Kidney Foundation. K/DOQI clinical guidelines and clinical practice recommendation for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49 Suppl 2.
z. Yanagawa M. Evaluation of GFR using radioisotopes. In: Guidelines for determination of GFR and urinary protein, edited by Japanese Society of Nephrology, Tokyo Igakusha, Tokyo; 2003. p. 66–70
1.
Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003;42:677–84.PubMedCrossRef
2.
Kovesdy CP, Trivedi BK, Anderson JE. Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis:a historical prospective cohort study. Adv Chronic Kidney Dis. 2006;13:183–8.PubMedCrossRef
3.
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Int Med. 2004;164:659–63.CrossRef
4.
Patel UD, Young EW, Ojo AO, Hayward RA. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis. 2005;46:406–14.PubMedCrossRef
5.
Evans M, Fryzek JP, Elinder CG, Cohen SS, McLaughlin JK, Nyrén O, et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis. 2005;46:863–70.PubMedCrossRef
6.
Serrano A, Huang J, Ghossein C, Nishi L, Gangavathi A, Madhan V, et al. Stabilization of glomerular filtration rate in advanced chronic kidney disease: a two-year follow-up of a cohort of chronic kidney disease patients stages 4 and 5. Adv Chronic Kidney Dis. 2007;14:105–12.PubMedCrossRef
7.
Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol. 2006;17:2928–36.PubMedCrossRef
8.
Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433–41.PubMedCrossRef
9.
Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol. 2006;17:1444–52.PubMedCrossRef
10.
Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.PubMedCrossRef
11.
Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, et al. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. J Am Soc Nephrol. 2005;16:1775–80.PubMedCrossRef
12.
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Int Med. 1995;123:754–62.PubMedCrossRef
13.
Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Int Med. 2005;165:947–53.CrossRef
14.
Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–90.PubMedCrossRef
15.
Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281–7.PubMedCrossRef
16.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Angiotensin-converting enzymne inhibition and progression of renal disease. proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–40.PubMedCrossRef
17.
Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J. 1984;108:1347–52.PubMedCrossRef
18.
19.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
20.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–269.CrossRefPubMed
21.
Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228–36.PubMedCrossRef
22.
Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study. Nephrol Dial Transplant. 2007;22:1910–5.PubMedCrossRef
23.
Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.PubMedCrossRef
24.
Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18:1307–15.PubMedCrossRef
25.
Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Int Med. 2005;165:2659–65.CrossRef
26.
Weiner DE, Tighiouart H, Levey AS, Elsayed E, Griffith JL, Salem DN, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol. 2007;18:960–6.PubMedCrossRef
27.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
28.
Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–71.PubMedCrossRef
29.
Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47–55.PubMedCrossRef
30.
Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Int Med. 1997;157:1413–8.CrossRef
31.
Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–6.PubMedCrossRef
32.
Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Int Med. 2003;139:901–6.PubMedCrossRef
33.
Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.PubMedCrossRef
34.
Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32–5.PubMedCrossRef
35.
Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809–16.PubMedCrossRef
36.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921–7.PubMedCrossRef
37.
Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlof B, Devereux RB, et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens. 2006;24:775–81.PubMedCrossRef
1.
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002;62:956–62.CrossRefPubMed
2.
Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.PubMedCrossRef
3.
Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23, 534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003;14:2934–41.PubMedCrossRef
4.
Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA. 1991;265:614–7.PubMedCrossRef
5.
Ikeda Y, Suehiro T, Takamatsu K, Yamashita H, Tamura T, Hashimoto K. Effect of smoking on the prevalence of albuminuria in Japanese men with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1997;36:57–61.PubMedCrossRef
6.
Jones-Burton C, Seliger SL, Scherer RW, Mishra SI, Vessal G, Brown J, et al. Cigarette smoking and incident chronic kidney disease: a systematic review. Am J Nephrol. 2007;27:342–51.PubMedCrossRef
7.
Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17:126–31.PubMedCrossRef
8.
Orth SR, Schroeder T, Ritz E, Ferrari P. Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus. Nephrol Dial Transplant. 2005;20:2414–9.PubMedCrossRef
9.
Ejerblad E, Fored CM, Lindblad P, Fryzek J, Dickman PW, Elinder CG, et al. Association between smoking and chronic renal failure in a nationwide population-based case–control study. J Am Soc Nephrol. 2004;15:2178–85.PubMedCrossRef
10.
Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14:479–87.PubMed
11.
Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant. 1997;12:2597–602.PubMedCrossRef
12.
Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16:529–38.PubMedCrossRef
13.
Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737–45.PubMedCrossRef
14.
Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006;164:263–71.PubMedCrossRef
15.
Eidemak I, Haaber AB, Feldt-Rasmussen B, Kanstrup IL, Strandgaard S. Exercise training and the progression of chronic renal failure. Nephron. 1997;75:36–40.PubMedCrossRef
16.
Pechter U, Ots M, Mesikepp S, Zilmer K, Kullissaar T, Vihalemm T, et al. Beneficial effects of water-based exercise in patients with chronic kidney disease. Int J Rehabil Res. 2003;26:153–6.PubMedCrossRef
17.
Collins AJ, Foley R, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis. 2008;51:S1–320.PubMed
1.
Fouque D, Laville M, Boissel JP. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev. 2006;19(2):CD001892.
2.
Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. Nephrol Dial Transplant. 2000;15:1986–92.PubMedCrossRef
3.
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Int Med. 1996;124:627–32.PubMedCrossRef
4.
Fouque D, Laville M, Boissel JP, Chifflet R, Labeeuw M, Zech PY. Controlled low protein diets in chronic renal insufficiency: meta-analysis. BMJ. 1992;304:216–20.PubMedPubMedCentralCrossRef
5.
Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31:954–61.PubMedCrossRef
6.
Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW, et al. Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis. 2006;48:879–88.PubMedCrossRef
7.
Rosman JB, ter Wee PM, Meijer S, Piers-Becht TP, Sluiter WJ, Donker AJ. Prospective randomised trial of early dietary protein restriction in chronic renal failure. Lancet. 1984;2:1291–6.PubMedCrossRef
8.
Rosman JB, Langer K, Brandl M, Piers-Becht TP, van der Hem GK, ter Wee PM, et al. Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications. Kidney Int. 1989;27(1):S96–102.
9.
Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet. 1991;337:1299–304.PubMedCrossRef
10.
Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991;324:78–84.PubMedCrossRef
11.
D’Amico G, Gentile MG, Fellin G, Manna G, Cofano F. Effect of dietary protein restriction on the progression of renal failure: a prospective randomized trial. Nephrol Dial Transplant. 1994;9:1590–4.PubMed
12.
Cianciaruso B, Bellizzi V, Capuano A, Bovi G, Nastasi A, Conte G, et al. Short-term effects of low protein-normal sodium diet on renal function in chronic renal failure. Kidney Int. 1994;45:852–60.PubMedCrossRef
13.
Meloni C, Morosetti M, Suraci C, Pennafina MG, Tozzo C, Taccone-Gallucci M, et al. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr. 2002;12:96–101.PubMedCrossRef
14.
Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr. 2004;14:208–13.PubMedCrossRef
15.
Maschio G, Oldrizzi L, Tessitore N, D’Angelo A, Valvo E, Lupo A, et al. Effects of dietary protein and phosphorus restriction on the progression of early renal failure. Kidney Int. 1982;22:371–6.PubMedCrossRef
16.
Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62:220–8.PubMedCrossRef
17.
Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid-Smith PS. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med. 1989;321:1773–7.PubMedCrossRef
18.
Feiten SF, Draibe SA, Watanabe R, Duenhas MR, Baxmann AC, Nerbass FB, et al. Short-term effects of a very-low-protein diet supplemented with ketoacids in nondialyzed chronic kidney disease patients. Eur J Clin Nutr. 2005;59:129–36.PubMedCrossRef
19.
Gretz N, Korb E, Strauch M. Low-protein diet supplemented by keto acids in chronic renal failure: a prospective controlled study. Kidney Int. 1983;16 Suppl:S263–7.
20.
Ideura T, Shimazui M, Higuchi K, Morita H, Yoshimura A. Effect of nonsupplemented low-protein diet on very late stage CRF. Am J Kidney Dis. 2003;41(3 Suppl 1):S31–4.PubMedCrossRef
21.
Jungers P, Chauveau P, Ployard F, Lebkiri B, Ciancioni C, Man NK. Comparison of ketoacids and low protein diet on advanced chronic renal failure progression. Kidney Int. 1987;22 Suppl:S67–71.
22.
Ideura T, Shimazui M, Morita H, Yoshimura A. Protein intake of more than 0.5 g/kg BW/day is not effective in suppressing the progression of chronic renal failure. Contrib Nephrol. 2007;155:40–9.PubMedCrossRef
23.
Prakash S, Pande DP, Sharma S, Sharma D, Bal CS, Kulkarni H. Randomized, double-blind, placebo-controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure. J Ren Nutr. 2004;14:89–96.PubMedCrossRef
24.
Mircescu G, Garneata L, Stancu SH, Capusa C. Effects of a supplemented hypoproteic diet in chronic kidney disease. J Ren Nutr. 2007;17:179–88.PubMedCrossRef
25.
Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10.PubMedCrossRef
26.
Swift PA, Markandu ND, Sagnella GA, He FJ, MacGregor GA. Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. Hypertension. 2005;46:308–12.PubMedCrossRef
27.
Cianciaruso B, Bellizzi V, Minutolo R, Tavera A, Capuano A, Conte G, et al. Salt intake and renal outcome in patients with progressive renal disease. Miner Electrolyte Metab. 1998;24:296–301.PubMedCrossRef
28.
Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant. 1998;13:1682–5.PubMedCrossRef
a. Dietary reference intakes for Japanese (2005). The report from the scientific committee of “Dietary reference intakes for Japanese: Recommended dietary allowance”. Ministry of Health, Labour and Welfare, Japan. Daiichi Shuppan, Tokyo, 2005
1.
Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13 Suppl 5:80–93.CrossRef
2.
Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA. 1992;268:3085–91.PubMedCrossRef
3.
Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646–61.PubMedCrossRef
4.
Andersen MJ, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis. 2005;45:994–1001.PubMedCrossRef
5.
Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69:406–11.PubMedCrossRef
6.
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Int Med. 1995b;23:754–62.CrossRef
7.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Int Med. 2003;139:244–52.PubMedCrossRef
8.
Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Int Med. 2001b;135:73–87.PubMedCrossRef
9.
MacKinnon M. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8–20.PubMedCrossRef
10.
Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427–31.PubMedPubMedCentralCrossRef
11.
Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22:1613–22.PubMedCrossRef
12.
Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004b;351:1285–95.PubMedCrossRef
13.
Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006b;69:1264–71.PubMedCrossRef
14.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004b;351:1296–305.CrossRefPubMed
15.
Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, MeClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney lnt. 2003;64:610–5.CrossRef
16.
Koren-Morag N, GoIdbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular diseases. Neurology. 2006;67:224–8.PubMedCrossRef
17.
Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study. Nephrol Dial Transplant. 2007b;22:1910–5.PubMedCrossRef
18.
Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–33.PubMedCrossRef
19.
Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001b;286:421–6.PubMedCrossRef
20.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004b;110:921–7.PubMedCrossRef
21.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004c;65:2309–20.PubMedCrossRef
22.
Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:181–2.CrossRef
1.
Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the third national health and nutrition examination survey (1988–1994). Arch Int Med. 2002;162:1401–8.CrossRef
2.
Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16:1803–10.PubMedCrossRef
3.
Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16:3403–10.PubMedCrossRef
4.
Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955–62.PubMedCrossRef
5.
Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000;35:250–6.PubMedCrossRef
6.
Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis. 1994;24:777–84.PubMedCrossRef
7.
Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–80.PubMedCrossRef
8.
Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–85.PubMedCrossRef
11.
Ritz E, Laville M, Bilous RW, O’Donoghue D, Scherhag A, Burger U, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACOR) Study. Am J Kidney Dis. 2007;49:194–207.PubMedCrossRef
12.
Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66:753–60.PubMedCrossRef
13.
Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.PubMedCrossRef
14.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.PubMedCrossRef
15.
Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–8.PubMedCrossRef
16.
Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791–8.PubMedPubMedCentralCrossRef
1.
Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520–8.PubMedCrossRef
2.
Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:825–31.PubMedCrossRef
3.
Ritz E, Küster S, Schmidt-Gayk H, Stein G, Scholz C, Kraatz G, et al. Low-dose calcitriol prevents the rise in 1, 84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant. 1995;10:2228–34.PubMedCrossRef
4.
Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263–76.PubMedCrossRef
5.
Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823–8.PubMedCrossRef
6.
Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant. 2004;19:870–6.PubMedCrossRef
7.
Panichi V, Andreini B, De Pietro S, Migliori M, Taccola D, Giovannini L, et al. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Clin Nephrol. 1998;49:245–50.PubMed
8.
Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310:358–63.PubMedPubMedCentralCrossRef
9.
Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008;19:1613–9.PubMedPubMedCentralCrossRef
a. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Kidney Disease:Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease:Improving Global Outcomes(KDIGO). Kidney Int. 2006;69:1945–53PubMedCrossRef
1.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
2.
Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304–9.PubMedCrossRef
3.
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.PubMedCrossRef
4.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
5.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.PubMedCentralCrossRef
6.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ. 1998b;317:713–20.PubMedCentralCrossRef
7.
Schnack C, Hoffmann W, Hopmeier P, Schernthaner G. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia. 1996;39:1611–6.PubMedCrossRef
8.
Shiba T, Inoue M, Tada H, Hayashi Y, Okuda Y, Fujita R, et al. Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. Diabetes Res Clin Pract. 2000;47:97–104.PubMedCrossRef
9.
Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Batnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens. 1996;10:185–92.PubMed
10.
Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9.CrossRef
11.
Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996;45:216–22.PubMedCrossRef
12.
Baba S. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001;54:191–201.PubMedCrossRef
13.
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941–51.PubMedCrossRef
14.
Sengul AM, Altuntas Y, Kürklü A, Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract. 2006;71:210–9.PubMedCrossRef
15.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.PubMedCrossRef
16.
Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis. 1999;34:809–17.PubMedCrossRef
17.
Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.PubMedCrossRef
18.
Barnett AH. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol. 2006;17:S132–5.PubMedCrossRef
19.
Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Int Med. 1998;128:982–8.PubMedCrossRef
20.
Ogawa S, Takeuchi K, Mori T, Naka K, Tsubono Y, Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res. 2007;30:325–34.PubMedCrossRef
21.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.PubMedCrossRef
22.
Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672–8.PubMedCrossRef
23.
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577–8.PubMedCrossRef
24.
Shiga Microalbuminuria Reduction Trial (SMART) Group, Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care. 2007;30:1581–3.CrossRef
25.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.PubMedCrossRef
26.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.PubMedCrossRef
27.
Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care. 1994;17:420–4.PubMedCrossRef
28.
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med. 1993;118:577–81.PubMedCrossRef
29.
Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20:1576–81.PubMedCrossRef
30.
Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271:275–9.PubMedCrossRef
31.
Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995;99:497–504.PubMedCrossRef
32.
The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 1996;39:587–93.CrossRef
33.
Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care. 1998;21:104–10.PubMedCrossRef
34.
Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract. 2002;55:113–21.PubMedCrossRef
35.
ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Int Med. 2001;134:370–9.CrossRef
36.
Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991b;324:78–84.PubMedCrossRef
37.
Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ. Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care. 1993;16:483–92.PubMedCrossRef
38.
Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002b;62:220–8.PubMedCrossRef
39.
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Int Med. 1996b;124:627–32.PubMedCrossRef
40.
Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998b;31:954–61.PubMedCrossRef
41.
Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD002181
42.
Pijls LT, de Vries H, Donker AJ, van Eijk JT. The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant. 1999;14:1445–53.PubMedCrossRef
43.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.PubMedCrossRef
44.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;7(358):580–91.CrossRef
1.
Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29:526–32.PubMedCrossRef
2.
Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006;21:2800–8.PubMedCrossRef
3.
Schena FP, Montenegro M, Scivittaro V. Meta-analysis of randomised controlled trials in patients with primary IgA nephropathy (Berger’s disease). Nephrol Dial Transplant. 1990;5 Suppl 1:47–52.PubMedCrossRef
4.
Strippoli GF, Manno C, Schena FP. An “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis. 2003;41:1129–39.PubMedCrossRef
5.
Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578–83.PubMedCrossRef
6.
Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE:a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880–8.PubMedCrossRef
7.
Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron. 1996;72:237–42.PubMedCrossRef
8.
Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology. 2004;9:177–85.PubMedCrossRef
9.
Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.PubMedCrossRef
10.
Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.PubMedCrossRef
11.
Miyazaki M, Hotta O, Komatsuda A, Nakai S, Shoji T, Yasunaga C, et al. A multicenter prospective cohort study of tonsillectomy and steroid therapy in Japanese patients with IgA nephropathy: a 5-year report. Contrib Nephrol. 2007;157:94–8.PubMed
12.
Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.PubMedPubMedCentralCrossRef
13.
Sato M, Hotta O, Tomioka S, Horigome I, Chiba S, Miyazaki M, et al. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy. Nephron Clin Pract. 2003;93:137–45.CrossRef
14.
Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol. 2006;10:268–73.PubMedCrossRef
1.
Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25:862–75.PubMedCrossRef
2.
Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J Am Soc Nephrol. 1995;5:1553–8.PubMed
3.
Schieppati A, Perna A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2004;18:CD004293.
4.
Jha V, Ganguli A, Saha TK, Kohli HS, Snd K, Gupta KL, et al. A randomized, controlled trial of steroid and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18:1899–904.PubMedCrossRef
5.
Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989;320:8–13.PubMedCrossRef
6.
Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48:1600–4.PubMedCrossRef
7.
Ponticelli C, Zucchelli P, Passerini P, Cesana B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med. 1992;327:599–603.PubMedCrossRef
8.
Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9:444–50.PubMed
9.
Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy:a randomized trial. Kidney Int. 2001;59:1484–90.PubMedCrossRef
10.
Banfi G, Moriggi M, Sabadini E, Fellin G, D’Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol. 1991;36:53–9.PubMed
11.
Agarwal SK, Dash SC, Tiwari SC, Bhuyan UN. Idiopathic adult focal segmental glomerulosclerosis: a clinicopathological study and response to steroid. Nephron. 1993;63:168–71.PubMedCrossRef
12.
Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis. 1995;25:534–42.PubMedCrossRef
13.
Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56:2220–6.PubMedCrossRef
14.
Heering P, Braun N, Mullejans R, Ivens K, Zauner I, Funfstuck R, et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis. 2004;43:10–8.PubMedCrossRef
15.
Walker RG, Kincaid-Smith P. The effect of treatment of corticosteroid-resistant idiopathic(primary)focal and segmental hyalinosis and sclerosis(focal glomerulosclerosis)with ciclosporin. Nephron. 1990;54:117–21.PubMedCrossRef
16.
Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, Risler T, Willis NS. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2008;3:CD003233.
a. Sakai H, Kurokawa K, Saito T, Shiiki H, Nishi S, Mitarai T, Yokoyama H, Yoshimura A, Yorioka N. Guideline for treatment of unrefractory nephrotic syndrome in adults. The report from the scientific committee of “Progressive kidney diseases; Specific Diseases Appointed by Ministry of Health, Labour and Welfare, Japan”. Nippon Jinzo Gakkai Shi. 2002;44:751–61PubMed
1.
Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis:a randomized controlled trial. JAMA. 2001;285:2719–28.PubMedCrossRef
2.
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–31.PubMedCrossRef
3.
Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, et al. The relationship between magnitude of proteinuria reduction and risk of end–stage renal disease: results of the African American study of kidney disease and hypertension. Arch Int Med. 2005b;165:947–53.CrossRef
4.
Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D, et al. Blood pressure control, drug therapy, and kidney disease. Hypertension. 2005;46:44–50.PubMedCrossRef
5.
Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Traial. AASK Pilot Study Investigators. Kidney Int. 1997;51:244–52.PubMedCrossRef
6.
Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ. 1994;309:833–7.PubMedPubMedCentralCrossRef
7.
Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care. 2006;29:595–600.PubMedCrossRef
8.
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Int Med. 2008;148:30–48.PubMedCrossRef
1.
Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Int Med. 2001;135:401–11.PubMedCrossRef
2.
Williams GJ, Macaskill P, Chan SF, Karplus TE, Yung W, Hodson EM, et al. Comparative accuracy of renal duplex sonographic parameters in the diagnosis of renal artery stenosis: paired and unpaired analysis. Am J Roentgenol. 2007;188:798–811.CrossRef
3.
Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, Maki JH, Leiner T, Beek FJ, Korst MB, Flobbe K, de Haan MW, van Zwam WH, Postma CT, Hunink MG, de Leeuw PW, van Engelshoven JM;Renal Artery Diagnostic Imaging Study in Hypertension(RADISH)Study Group. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Int Med. 2004;141:674–82.
4.
Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens. 1998;12:329–35.PubMedCrossRef
5.
Plouin PF, Chatellier G, Darné B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs. Angioplastie (EMMA) Study Group. Hypertension. 1998;31:823–9.PubMedCrossRef
6.
van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, et al. Randomised comparison of percutaneous angioplasty vs. continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Study Group. N Engl J Med. 2000;342:1007–14.PubMedCrossRef
7.
Ives NJ, Wheatley K, Stowe RL, Krijnen P, Plouin PF, van Jaarsveld BC, et al. Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. Nephrol Dial Transplant. 2003;18:298–304.PubMedCrossRef
8.
Nordmann AJ, Woo K, Parkes R, Logan AG. Balloon angioplasty or medical therapy for hypertensive patients with atherosclerotic renal artery stenosis? A meta-analysis of randomized controlled trials. Am J Med. 2003;114:44–50.PubMedCrossRef
9.
Balk E, Raman G, Chung M, Ip S, Tatsioni A, Alonso A, et al. Effectiveness of management strategies for renal artery stenosis: a systematic review. Ann Int Med. 2006;145:901–12.PubMedCrossRef
1.
Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Int Med. 2005;142:342–51.PubMedCrossRef
2.
Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol. 1995;5:2037–47.PubMed
3.
Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW, et al. Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis. 2006b;48:879–88.PubMedCrossRef
1.
Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–91.PubMed
2.
Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26:670–5.PubMedCrossRef
3.
Mulec H, Johnsen SA, Wiklund O, Björck S. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis. 1993;22:196–201.PubMedCrossRef
4.
Breyer JA, Bain RP, Evans JK, Nahman NS Jr, Lewis EJ, Cooper M, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int. 1996;50:1651–8.PubMedCrossRef
5.
Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Int Med. 1998b;158:998–1004.CrossRef
6.
Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia—a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int. 1994;45 Suppl:S125–31.
7.
Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA. Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, Brenner BM;RENAAL Study. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26:1402–7.PubMedCrossRef
8.
Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908–19.PubMedCrossRef
9.
Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301.PubMedCrossRef
10.
Hadjadj S, Duly-Bouhanick B, Bekherraz A, BrIdoux F, Gallois Y, Mauco G, et al. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab. 2004;30:43–51.PubMedCrossRef
11.
Massy ZA, Nguyen Khoa T, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant. 1999;14:2392–7.PubMedCrossRef
12.
Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005b;16:529–38.PubMedCrossRef
13.
Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44:638–42.PubMedCrossRef
14.
Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest. 2000;30:980–7.PubMedCrossRef
15.
Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002;40:67–73.PubMedCrossRef
16.
Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565–70.PubMedCrossRef
17.
Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–8.PubMedCrossRef
18.
Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260–9.PubMedCrossRef
19.
Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102:52–60.PubMedCrossRef
20.
Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation(GREACE)study. J Clin Pathol. 2004;57:728–34.PubMedPubMedCentralCrossRef
21.
Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol. 2006;97:1602–6.PubMedCrossRef
22.
Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC, Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605–13.PubMedCrossRef
23.
Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–63.PubMedCrossRef
24.
Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16:3748–54.PubMedCrossRef
25.
Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G, Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Int Med. 2003;138:98–104.PubMedCrossRef
26.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRef
27.
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, ASCOT investigators, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.
1.
Ramirez SP, McClellan W, Port FK, Hsu SIH. Risk factors for proteinuria in a large, multiracial, Southeast Asian population. J Am Soc Nephrol. 2002;13:1907–17.PubMedCrossRef
2.
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002;62:956–62.CrossRefPubMed
3.
Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.PubMedCrossRef
4.
Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CDK: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis. 2005;46:587–94.PubMedCrossRef
5.
Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005;46:871–80.PubMedCrossRef
6.
Hallan S, de Mutsert R, Carlsen S, Dekker FW, Aasarod K, Holmen J. Obesity, smokimg, and physical inactivity as risk factors for CKD: are men more vulnerable ? Am J Kidney Dis. 2006;47:396–405.PubMedCrossRef
7.
Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.PubMedCrossRef
8.
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Int Med. 2006;144:21–8.PubMedCrossRef
9.
Iseki K, Ikemiya K, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870–6.PubMedCrossRef
10.
Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyrén O. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.PubMedCrossRef
11.
Speckman RA, McClellan WM, Volkova NV, Jurkovitz CT, Satko SG, Schoolwerth AC, et al. Obesity is associated with family history of ESRD in incident dialysis patients. Am J Kidney Dis. 2006;48:50–8.PubMedCrossRef
12.
Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezene F, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis. 2001;37:720–7.PubMedCrossRef
13.
Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Diaz-Gonzalez R, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000;58:2111–8.PubMedCrossRef
14.
Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int. 2005;68:263–70.PubMedCrossRef
15.
Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE, et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis. 2003;41:733–41.PubMedCrossRef
16.
Bonnet F, Marre M, Halimi JM, Stengel B, Lange C, Laville M, et al. DESIR Study. Weight circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens. 2006;24:1157–63.PubMedCrossRef
17.
de Boer IH, Sibley SD, Kestenbaum B, Sampson JN, Young B, Cleary PA, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol. 2007;18:235–43.PubMedCrossRef
18.
Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi D, Parodi A, et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Int Med. 2005;257:454–60.CrossRef
19.
Mulé G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G, et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Int Med. 2005;257:503–13.CrossRef
20.
Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Int Med. 2004;140:167–74.PubMedCrossRef
21.
Kurella M, Lo CJ, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–40.PubMedCrossRef
22.
Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69:369–74.PubMedCrossRef
23.
Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: The Hisayama Study. Am J Kidney Dis. 2006;48:383–91.PubMedCrossRef
24.
Miyatake N, Wada J, Kawasaki Y, Matsumoto S, Makino H, Numata T. Relationship between metabolic syndrome and proteinuria in the Japanese population. Int Med. 2006;45:599–603.CrossRef
25.
Iseki K, Kohagura K, Sakime A, Iseki C, Kinjo K, Ikemiya Y, et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res. 2007;30:55–62.PubMedCrossRef
26.
Tsuda S, Nakano S, Konishi K, Koya D. A lack of increase in high molecular weight-adiponectin in macroalbuminuric subjects with metabolic syndrome may exert renal and atherosclerotic risks. Diabetes Res Clin Pract. 2008;79:503–9.PubMedCrossRef
27.
Chen J, Gu D, Chen CS, Wu X, Hamm LL, Muntner P, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22:1100–6.PubMedCrossRef
28.
Kitiyakara C, Yamwong S, Cheepudomwit S, Domrongkitchaiporn S, Unkurapinun N, Pakpeankitvatana V, et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int. 2007;71:693–700.PubMedCrossRef
29.
Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control(the FinnDiane study). Diabetes Care. 2005;28:2019–24.PubMedCrossRef
30.
Rashidi A, Ghanbarian A, Azizi F. Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol. 2007;2:976–83.PubMedCrossRef
31.
Morales E, Valero A, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319–27.PubMedCrossRef
32.
Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes. 2005;29:1115–20.CrossRef
33.
Bello AK, de Zeeuw D, El Nahas M, Brantsma AH, Bakke SJ, de Jong PE, et al. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant. 2007;22:1619–27.PubMedCrossRef
34.
AHEAD The Look Research Group. Reduction in weight and cardiovascular risk factors in individuals with type 2 diabetes. One-year results of the Look AHEAD trial. Diabetes Care. 2007;30:1373–83.CrossRef
1.
Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111:1416–21.PubMedCrossRef
2.
Heilbron DC, Holliday MA, al-Dahwi A, Kogan BA. Expressing glomerular filtration rate in children. Pediatr Nephrol. 1991;5:5–11.PubMedCrossRef
3.
Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney disease. Pediatr Nephrol. 2007;22:1839–48.PubMedCrossRef
4.
Kojima Y. Creatinine; serum standard values in Japanese children, In: Nihon Koshueisei Kyokai, ed by Study Group of children’s physiological values, 1996;137–40
5.
Nishida T, Hayashi Y, Nakamura Y. Differences in clinical reference values between different ages and sexes. Rinsho Byori. 1984;32:1263–70.PubMed
6.
Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259–63.PubMed
7.
Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34:571–90.PubMedCrossRef
8.
9.
Ardissino G, Daccò V, Testa S, Bonaudo R, Claris-Appiani A, Taioli E, et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics. 2003;111:e382–7.PubMedCrossRef
10.
Hattori S, Yosioka K, Honda M, Ito H, Japanese Society for Pediatric Nephrology. The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients. Pediatr Nephrol. 2002;17:456–61.PubMedCrossRef
11.
Wong H, Mylrea K, Feber J, Drukker A, Filler G. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int. 2006;70:585–90.PubMedCrossRef
12.
Hattori S. Epidemiologic survey of renal failure in children. Rinsho Toseki. 2005;21:1315–22.
13.
Udagawa J, Kurayama H, Matsumuta C, Akikusa B. Preventive effect of school urine screening test on development of renal failure. Jpn J Pediatr Nephrol. 2000;13:113–7.
14.
Murakami M. School urine analysis as a method for mass screening. Shouni Hoken Kenkyu. 2004;63:365–70.
15.
16.
Yoshimoto M, Tsukahara H, Saito M, Hayashi S, Haruki S, Fujisawa S, et al. Evaluation of variability of proteinuria indices. Pediatr Nephrol. 1990;4:136–9.PubMedCrossRef
17.
Abitbol C, Zilleruelo G, Freundlich M, Strauss J. Quantitation of proteinuria with urinary protein/creatinine ratios and random testing with dipsticks in nephrotic children. J Pediatr. 1990;116:243–7.PubMedCrossRef
18.
Rytand DA, Spreiter S. Prognosis in postural (orthostatic) proteinuria: forty to fifty-year follow-up of six patients after diagnosis by Thomas Addis. N Engl J Med. 1981;305:618.PubMedCrossRef
19.
de Bruyn R, Gordon I. Postnatal investigation of fetal renal disease. Prenat Diagn. 2001;21:984–91.PubMedCrossRef
20.
Shishido S, Aikawa A, Ooshima S, Hasegawa A, Hattori M, Yoshimura R. Present status and long term outcome of renal transplantation in children. Nihon Ishoku Gakkaishi. 2007;42:347–53.
21.
McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350:2654–62.PubMedCrossRef
22.
Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR, Van De Kar NJ, et al. Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int. 2002;61:621–9.PubMedCrossRef
23.
Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr. 2002;141:191–7.PubMedCrossRef
24.
Seikaly MG, Salhab N, Gipson D, Yiu V, Stablein D. Stature in children with chronic kidney disease: analysis of NAPRTCS database. Pediatr Nephrol. 2006;21:793–9.PubMedCrossRef
25.
Wada N. Long term prognosis of growth failure in patients with peritoneal dialysis who do not use gwoth hormone. Shoni PD Kenkyukaishi. 2000;13:32–5.
26.
Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M, et al. Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol. 2008;23:905–12.PubMedPubMedCentralCrossRef
27.
Wyatt RJ, Kritchevsky SB, Woodford SY, Miller PM, Roy S 3rd, Holland NH, et al. IgA nephropathy: long-term prognosis for pediatric patients. J Pediatr. 1995;127:913–9.PubMedCrossRef
28.
Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino D. Prognostic indicators in children with IgA nephropathy—report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 1994;8:15–20.PubMedCrossRef
29.
Yoshikawa N, Ito H, Nakamura H. Prognostic indicators in childhood IgA nephropathy. Nephron. 1992;60:60–7.PubMedCrossRef
30.
Hisano S, Kawano M, Kaku Y, Yamane I, Hatae K, Uragoh K, et al. The natural history of screening detected IgA glomerulonephritis in children. Acta Paediatr Scand. 1991;80:1044–50.PubMedCrossRef
31.
Hattori S, Karashima S, Furuse A, Terashima T, Hiramatsu M, Murakami M, et al. Clinicopathological correlation of IgA nephropathy in children. Am J Nephrol. 1985;5:182–9.PubMedCrossRef
32.
Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, et al. Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis. 2006;47:993–1003.PubMedCrossRef
33.
Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet. 1992;339(8788):280–2.PubMedCrossRef
34.
Emre S, Bilge I, Sirin A, Kilicaslan I, Nayir A, Oktem F, et al. Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron. 2001;87:118–26.PubMedCrossRef
35.
Bogdanović R, Nikolicć V, Pasić S, Dimitrijevié J, Lipkovska-Marković J, Erić-Marinković J, et al. Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol. 2004;19:36–44.PubMedCrossRef
36.
White RH, Raafat F, Milford DV, Komianou F, Moghal NE. The Alport nephropathy: clinicopathological correlations. Pediatr Nephrol. 2005;20:897–903.PubMedCrossRef
37.
Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history and genotype–phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol. 2003;14:2603–10.PubMedCrossRef
38.
Peña A, Bravo J, Melgosa M, Fernandez C, Meseguer C, Espinosa L, et al. Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy. Pediatr Nephrol. 2007;22:1875–80.PubMedCrossRef
39.
Roth KS, Carter WH Jr, Chan JC. Obstructive nephropathy in children: long-term progression after relief of posterior urethral valve. Pediatrics. 2001;107:1004–10.PubMedCrossRef
40.
Ismaili K, Schurmans T, Wissing KM, Hall M, Van Aelst C, Janssen F. Early prognostic factors of infants with chronic renal failure caused by renal dysplasia. Pediatr Nephrol. 2001;16:260–4.PubMedCrossRef
41.
Van Dyck M, Bilem N, Proesmans W. Conservative treatment for chronic renal failure from birth: a 3-year follow-up study. Pediatr Nephrol. 1999;13:865–9.PubMedCrossRef
42.
Oliveira EA, Diniz JS, Cabral AC, Leite HV, Colosimo EA, Oliveira RB, et al. Prognostic factors in fetal hydronephrosis: a multivariate analysis. Pediatr Nephrol. 1999;13:859–64.PubMedCrossRef
a. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004–1010.
b. Hogg RJ, Portmann RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children:Recommendations from a pediatric nephrology panel established at the National Kidney Foundation Conference on Proteinuria, Risk, Assessment, Detection, Elimination (PARADE). Pediatrics. 2000;105:1242–9.PubMedCrossRef
c. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 (2 Suppl 1):S1–266.
d. Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease. ed by Japanese Society of Nephrology; 2007
e. Guideline for renal function (GFR) and measument of urinary protein. ed by Japanese Society of Nephrology; 2007
f. Treatment guidelines for the idiopathic nephrotic syndrome in children (ver. 1). ed by Japanese Society for Pediatric Nephrology, Committee for Development of Guidelines for Drug Therapy for Nephrotic Syndrome in Children. https://​doi.​org/​www.​jspn.​jp/​ J Jpn Pediatr Soc. 2005;109:1066–75. Nippon Jinzo Gakkai Shi. 2005;47:790–803. Jpn J Pediatr Nephrol. 2005;18:170–81.
g. Guidelines for diagnosis of hematuria. Commitee for Diagnostic Guidelines of Hematuria. Nippon Jinzo Gakkai Shi. 2006;48 Suppl:1–34. Jpn J Urol. 2006;97 Suppl:1–35.
h. Guidebook of the renal biopsy. ed by Japanese Society of Nephrology; 2004
1.
Hattori S, Yoshikawa N, Ichikawa I, Honda M, Igarashi T. The 2003 report of the national registry data on pediatric end-stage renal disease patients. Jpn J Pediatr Noephrol. 2004;17:121–30.
2.
Seikaly MG, Ho PL, Emmett L, Fine RN, Tejani A. Chronic renal insufficiency in children: the 2001 Annual Report of the NAPRTCS. Pediatr Nephrol. 2003;18:796–804.PubMedCrossRef
3.
Allen C, Glasziou P, Del Mar C. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet. 1999;354:1229–33.PubMedCrossRef
4.
Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362–74.PubMedCrossRef
5.
Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. JAMA. 2004;291:2107–13.PubMedCrossRef
6.
Savoye M, Shaw M, Dziura J, Tamborlane WV, Rose P, Guandalini C, et al. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA. 2007;297:2697–704.PubMedCrossRef
7.
Karlberg J, Schaefer F, Hennicke M, Wingen AM, Rigden S, Mehls O. Early age-dependent growth impairment in chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. Pediatr Nephrol. 1996;10:283–7.PubMedCrossRef
8.
Arnold WC, Danford D, Holliday MA. Effects of caloric supplementation on growth in children with uremia. Kidney Int. 1983;24:205–9.PubMedCrossRef
9.
Kari JA, Gonzalez C, Ledermann SE, Shaw V, Rees L. Outcome and growth of infants with severe chronic renal failure. Kidney Int. 2000;57:1681–7.PubMedCrossRef
10.
Chaturvedi S, Jones C. Protein restriction for children with chronic renal failure. Cochrane Database Systematic Rev. 2007 Issue 4
11.
Geleijnse JM, Hofman A, Witteman JC, Hazebroek AA, Valkenburg HA, Grobbee DE. Long-term effects of neonatal sodium restriction on blood pressure. Hypertension. 1997;29:913–7.PubMedCrossRef
12.
Kouda K, Nakamura H, Tokunaga R, Takeuchi H. Trends in levels of cholesterol in Japanese children from 1993 through 2001. J Epidemiol. 2004;14:78–82.PubMedCrossRef
13.
Neu AM, Warady BA, Furth SL, Lederman HM, Fivush BA. Antibody levels to diphtheria, tetanus, and rubella in infants vaccinated while on PD: a Study of the Pediatric Peritoneal Dialysis Study Consortium. Adv Perit Dial. 1997;13:297–9.PubMed
14.
Furth SL, Neu AM, McColley SA, Case B, Steinhoff M, Fivush B. Immune response to influenza vaccination in children with renal disease. Pediatr Nephrol. 1995;9:566–8.PubMedCrossRef
15.
Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA, et al. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J Pediatr. 2003;142:145–8.PubMedCrossRef
16.
Furth SL, Neu AM, Sullivan EK, Gensler G, Tejani A, Fivush BA. Immunization practices in children with renal disease: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 1997;11:443–6.PubMedCrossRef
17.
Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol. 1994;8:190–2.PubMedCrossRef
18.
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114 Suppl 4:555–76.CrossRef
19.
Tomizawa S, Uchiyama M, Kurayama A, Takahashi S, Suhara Y, Kadowaki J, et al. Dose study of long-active Nifedipine (Sepamit-R) in pediatric hypertension associated with kidney diseases. Shounika Rinsyo. 1996;59:303–10.
20.
Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353–9.PubMedCrossRef
21.
Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. A double-blind, placebo-controlled, dose–response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42:870–80.PubMedCrossRef
22.
Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose–response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16:795–800.PubMedCrossRef
23.
Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose–response study of losartan in hypertensive children. Am J Hypertens. 2005;18:183–90.PubMedCrossRef
24.
Norman ME, Mazur AT, Borden S 4th, Gruskin A, Anast C, Baron R, et al. Early diagnosis of juvenile renal osteodystrophy. J Pediatr. 1980;97:226–32.PubMedCrossRef
25.
Brodehl J, Gellissen K, Weber HP. Postnatal development of tubular phosphate reabsorption. Clin Nephrol. 1982;17:163–71.PubMed
26.
Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int. 1994;45:253–8.PubMedCrossRef
27.
Boehm M, Riesenhuber A, Winkelmayer WC, Arbeiter K, Mueller T, Aufricht C. Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr Nephrol. 2007;22:1189–93.PubMedCrossRef
28.
Fadrowski JJ, Pierce CB, Cole SR, Moxey-Mims M, Warady BA, Furth SL. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol. 2008;3:457–62.PubMedPubMedCentralCrossRef
29.
Schärer K, Klare B, Braun A, Dressel P, Gretz N. Treatment of renal anemia by subcutaneous erythropoietin in children with preterminal chronic renal failure. Acta Paediatr. 1993;82:953–8.PubMedCrossRef
30.
Van Damme-Lombaerts R, Broyer M, Businger J, Baldauf C, Stocker H. A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis. Pediatr Nephrol. 1994;8:338–42.PubMedCrossRef
31.
Frankenfield DL, Neu AM, Warady BA, Fivush BA, Johnson CA, Brem AS. Anemia in pediatric hemodialysis patients: results from the 2001 ESRD Clinical Performance Measures Project. Kidney Int. 2003;64:1120–4.PubMedCrossRef
32.
Burke JR. Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association. Pediatr Nephrol. 1995;9:558–61.PubMedCrossRef
33.
Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000;14:898–902.PubMedCrossRef
34.
Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol. 2003;18:1055–62.PubMedCrossRef
35.
Vimalachandra D, Hodson EM, Willis NS, Craig JC, Cowell C, Knight JF. Growth hormone for children with chronic kidney disease. Cochrane Database Systematic Rev. 2007 Issue 4
36.
Haffner D, Wuhl E, Schaefer F, Nissel R, Tonshoff B, Mehls O. Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Am Soc Nephrol. 1998;9:1899–907.PubMed
37.
Seikaly MG, Salhab N, Warady BA, Stablein D. Use of rhGH in children with chronic kidney disease: lessons from NAPRTCS. Pediatr Nephrol. 2007;22:1195–204.PubMedCrossRef
38.
The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. 1981;98:561–4.CrossRef
39.
Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 1997;8:769–76.PubMed
40.
Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of “Arbeitsgemeinschaft für Pädiatrische Nephrologie”. Lancet. 1979;1:401–3.
41.
Ueda N, Chihara M, Kawaguchi S, Niinomi Y, Nonoda T, Matsumoto J, et al. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr. 1988;112:122–6.PubMedCrossRef
42.
Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr. 1993;152:357–61.PubMedCrossRef
43.
Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, et al. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis. 2003;41:1155–62.PubMedCrossRef
44.
Mori K, Honda M, Ikeda M. Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:1232–6.PubMedCrossRef
45.
Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant. 2007;22:2183–93.PubMedCrossRef
46.
Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M, et al. Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol. 2008b;23:905–12.PubMedPubMedCentralCrossRef
47.
Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr. 2003;143:89–97.PubMedCrossRef
48.
Bhattacharjee R, Filler G. Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatr Nephrol. 2002;17:302–4.PubMedCrossRef
49.
Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol. 2005;64:35–40.PubMedCrossRef
50.
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol. 1999;10:101–9.PubMed
51.
Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:511–7.PubMedCrossRef
52.
Yoshikawa N, Nakanishi K, Ishikura K, Hataya H, Iijima K, Honda M. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2008;23:757–63.PubMedCrossRef
53.
Wuhl E, Mehls O, Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–76.PubMedCrossRef
54.
Franscini LM, Von Vigier RO, Pfister R, Casaulta-Aebischer C, Fossali E, Bianchetti MG. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens. 2002;15:1057–63.PubMedCrossRef
55.
Litwin M, Grenda R, Sladowska J, Antoniewicz J. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr Nephrol. 2006;21:1716–22.PubMedCrossRef
56.
Ardissino G, Viganò S, Testa S, Daccò V, Paglialonga F, Leoni A, et al. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy—report from the ItalKid Project database. Nephrol Dial Transplant. 2007;22:2525–30.PubMedCrossRef
57.
McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350:2654–62.PubMedCrossRef
58.
Honda M. The present status of peritonitis in pediatric peritoneal dialysis. Data from Committee on Pediatric PD. Jin to Touseki. 2000;49:283–6.
59.
Thomas SE, Hickman RO, Tapper D, Shaw DW, Fouser LS, McDonald RA. Asymptomatic inferior vena cava abnormalities in three children with end-stage renal disease: risk factors and screening guidelines for pretransplant diagnosis. Pediatr Transplant. 2000;4:28–34.PubMedCrossRef
60.
Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol. 2002;13:1358–64.PubMedCrossRef
61.
Cransberg K, Smits JM, Offner G, Nauta J, Persijn GG. Kidney transplantation without prior dialysis in children: the Eurotransplant experience. Am J Transplant. 2006;6:1858–64.PubMedCrossRef
62.
Vats AN, Donaldson L, Fine RN, Chavers BM. Pretransplant dialysis status and outcome of renal transplantation in North American children: a NAPRTCS Study. North American Pediatric Renal Transplant Cooperative Study. Transplantation. 2000;69:1414–9.PubMedCrossRef
63.
Shishido S, Asanuma H, Tajima E, Hoshinaga K, Ogawa O, Hasegawa A, et al. ABO-incompatible living-donor kidney transplantation in children. Transplantation. 2001;72:1037–42.PubMedCrossRef
64.
Hataya H, Ikeda M, Shishido S, Honda M. Treatment of recurrent post-transplant FSGS. Jpn J Pediatr Ren Failure. 2007;27:22–3.
65.
Ohta T, Kawaguchi H, Hattori M, Komatsu Y, Akioka Y, Nagata M, et al. Effect of pre- and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation. 2001;71:628–33.PubMedCrossRef
a. Edelmann CM. Pediatric kidney disease. 2nd ed. Boston: Little Brown; 1992.
b. Baratt TM, et al. Pediatric nephrology. 4th ed. Baltimore:Lippincott Williams and Willkins; 1999.
c. American Academy of Pediatrics. Active immunization. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village: American Academy of Pediatrics; 2006. p. 9–103.
d. KDOQI, National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis. 2005;46 Suppl 1:S1–121.
e. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant. 1999;14 Suppl 5:1–50.
f. KDOQI; National Kidney Foundation. III. Clinical practice recommendations for anemia in chronic kidney disease in children. Am J Kidney Dis. 2006;47 Suppl 3:S86–108.
g. The Japanese society for pediatric nephrology. Guidelines for the treatment of childhood idiopathic nephrotic syndrome, ver1.0.Nippon Jinzo Gakkai Shi, 2008;50:31–41.
h. Pediatric nephrology 5th ed. Steroid-sensitive idiopathic nephrotic syndrome in children. p. 543–53.
i. The Japanese society for pediatric nephrology. Guidelines for the treatment of childhood IgA nephropathy, ver1.0
j. UpToDate: treatment and prognosis of IgA nephropathy.
k. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS;National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111:1416–21.PubMedCrossRef
ℓ. Warady BA, Alexander SR, Watkins S, Kohaut E, Harmon WE. Optimal care of the pediatric end-stage renal disease patient on dialysis. Am J Kidney Dis. 1999;33:567–83.PubMedCrossRef
m. Honda M. Management of children with end stage renal failure. Nippon Shonika Gakkai Zasshi. 2004;108:3–11.
1.
Nakamura S, Nakata H, Yoshihara F, Kamide K, Horio T, Nakahama H, et al. Effect of early nephrology referral on the initiation of hemodialysis and survival in patients with chronic kidney disease and cardiovascular diseases. Circ J. 2007;71:511–6.PubMedCrossRef
2.
Martínez-Ramírez HR, Jalomo-Martínez B, Cortés-Sanabria L, Rojas-Campos E, Barragán G, Alfaro G, Cueto-Manzano AM. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis. 2006;47:78–87.PubMedCrossRef
3.
Goovaerts T, Jadoul M, Goffin E. Influence of a pre-dialysis education programme(PDEP)on the mode of renal replacement therapy. Nephrol Dial Transplant. 2005;20:1842–7.PubMedCrossRef
4.
Levin A, Lewis M, Mortiboy P, Faber S, Hare I, Porter EC, et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. Am J Kidney Dis. 1997;29:533–40.PubMedCrossRef
5.
Devins GM, Mendelssohn DC, Barre PE, Binik YM. Predialysis psychoeducational intervention and coping styles influence time to dialysis in chronic kidney disease. Am J Kidney Dis. 2003;42:693–703.PubMedCrossRef
6.
Inaguma D, Tatematsu M, Shinjo H, Suzuki S, Mishima T, Inaba S, et al. Effect of an educational program on the predialysis period for patients with chronic renal failure. Clin Exp Nephrol. 2006;10:274–8.PubMedCrossRef
7.
Survey Committee Japanese Society for Dialysis Therapy: An overview of regular dialysis treatment in Japan as of Dec. 31, 2006 (Advance report), Japanese Society for Dialysis Therapy, Tokyo; 2007. p. 45–53.
8.
Survey Committee Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec. 31, 2006 (CD-ROM version). Tokyo: Japanese Society for Dialysis Therapy; 2007.
9.
Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol. 2003;14:2851–60.PubMedCrossRef
10.
Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol. 2003;14:415–24.PubMedCrossRef
11.
Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int. 2004;66:2389–401.PubMedCrossRef
12.
Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Int Med. 2005;143:174–83.PubMedCrossRef
13.
Liem YS, Wong JB, Hunink MG, de Charro FT, Winkelmayer WC. Comparison of hemodialysis and peritoneal dialysis survival in the Netherlands. Kidney Int. 2007;71:153–8.PubMedCrossRef
14.
Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001;12:2158–62.PubMed
1.
Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–30.PubMedCrossRef
2.
Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med. 2001;344:726–31.PubMedCrossRef
3.
Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002;74:1377–81.PubMedCrossRef
4.
Karthikeyan V, Karpinski J, Nair RC, Knoll G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant. 2004;4:262–9.PubMedCrossRef
1.
Coresh J, W.ei GL, McQuillan G, Brancati FL, Levey AS, Jones C, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Int Med. 2001;161:1207–16.CrossRef
2.
Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA. 1992;268:3085–91.PubMedCrossRef
3.
Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.CrossRefPubMed
4.
Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, Moriera A. The significance of adult hematuria: 1, 000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol. 1989;141:350–5.PubMedCrossRef
5.
Grossfeld GD, Litwin MS, Wolf JS Jr, Hricak H, Shuler CL, Agerter DC, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy. Part II. Patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology. 2001;57:604–10.PubMedCrossRef
6.
Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int. 2000;57:2072–9.PubMedCrossRef
7.
Collins AJ, Foley R, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis. 2008;51:S1–320.PubMed
8.
Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. Nephrol Dial Transplant. 2000;15:1986–92.PubMedCrossRef
9.
Rosman JB, ter Wee PM, Meijer S, Piers-Becht TP, Sluiter WJ, Donker AJ. Prospective randomised trial of early dietary protein restriction in chronic renal failure. Lancet. 1984;2:1291–6.PubMedCrossRef
10.
Rosman JB, Langer K, Brandl M, Piers-Becht TP, van der Hem GK, ter Wee PM, Donker AJ. Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications. Kidney Int (Suppl). 1989;27:S96–102.
11.
D’Amico G, Gentile MG, Fellin G, Manna G, Cofano F. Effect of dietary protein restriction on the progression of renal failure: a prospective randomized trial. Nephrol Dial Transplant. 1994;9:1590–4.PubMed
12.
Meloni C, Morosetti M, Suraci C, Pennafina MG, Tozzo C, Taccone-Gallucci M, et al. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr. 2002;12:96–101.PubMedCrossRef
13.
Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr. 2004b;14:208–13.PubMedCrossRef
14.
Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid-Smith PS. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med. 1989b;321:1773–7.PubMedCrossRef
15.
Jungers P, Chauveau P, Ployard F, Lebkiri B, Ciancioni C, Man NK. Comparison of ketoacids and low protein diet on advanced chronic renal failure progression. Kidney Int (Suppl). 1987b;22:S67–71.
16.
Brunori G, Viola BF, Parrinello G, De Biase V, Como G, Franco V, et al. Efficacy and safety of a very-low-protein diet when postponing dialysis in the elderly: a prospective randomized multicenter controlled study. Am J Kidney Dis. 2007;49:569–80.PubMedCrossRef
17.
Luft FC, Fineberg NS, Weinberger MH. The influence of age on renal function and renin and aldosterone responses to sodium-volume expansion and contraction in normotensive and mildly hypertensive humans. Am J Hypertens. 1992;5:520–8.PubMedCrossRef
18.
Appel LJ, Espeland MA, Easter L, Wilson AC, Folmar S, Lacy CR. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Int Med. 2001;161:685–93.CrossRef
19.
Suzuki H, Saruta T, Calcium Antagonist in Progressive Renal Insufficienct Study Group. Effects of calcium antagonist, benidipine, on the progression of chronic renal failure in the elderly: a 1-year follow-up. Clin Exp Hypertens. 2001b;23:189–201.PubMedCrossRef
20.
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRef
21.
Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, et al. Hypertension and C. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Int Med. 2007;167:1884–91.CrossRef
22.
Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, et al. Antihypertensive drugs in very old people: a subgroup analysis of randomised controlled trials. Lancet. 1999;353:793–6.PubMedCrossRef
23.
Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–72.PubMedCrossRef
24.
Collaborative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.CrossRef
25.
Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L, Bailey JE, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Int Med. 1998;158:1340–5.CrossRef
26.
Masaki KH, Schatz IJ, Burchfiel CM, Sharp DS, Chiu D, Foley D, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation. 1998;98:2290–5.PubMedCrossRef
27.
Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Int Med. 1999;159:2004–9.CrossRef
28.
Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP, INDANA Project Steering Committee. Individual Data ANalysis of Antihypertensive intervention. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individualpatient data. Ann Int Med. 2002;136:438–48.PubMedCrossRef
29.
Campbell KH, O’Hare AM. Kidney disease in the elderly: update on recent literature. Curr Opin Nephrol Hypertens. 2008;17:298–303.PubMedCrossRef
30.
Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–64.PubMedCrossRef
31.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.CrossRef
32.
Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212–6.PubMedCrossRef
33.
Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA. 1998;279:1903–7.PubMedCrossRef
34.
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRef
35.
Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491–8.PubMedCrossRef
36.
Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Int Med. 2000;160:2645–50.CrossRef
37.
Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–52.PubMedCrossRef
38.
Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356:1955–64.PubMedCrossRef
39.
Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke:an overview of published reviews. Stroke. 2004;35:1024–33.PubMedCrossRef
40.
Mailloux LU, Napolitano B, Bellucci AG, Vernace M, Wilkes BM, Mossey RT. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience. Am J Kidney Dis. 1994;24:622–9.PubMedCrossRef
41.
Appel RG, Bleyer AJ, Reavis S, Hansen KJ. Renovascular disease in older patients beginning renal replacement therapy. Kidney Int. 1995;48:171–6.PubMedCrossRef
42.
Tanemoto M, Saitoh H, Satoh F, Satoh H, Abe T, Ito S. Predictors of undiagnosed renal artery stenosis among Japanese patients with risk factors of atherosclerosis. Hypertens Res. 2005;28:237–42.PubMedCrossRef
43.
Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC, et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older:Risk factors, revascularization, and prognosis. Kidney Int. 2005;68:293–301.PubMedCrossRef
44.
Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care. 1998;21:116–20.PubMedCrossRef
45.
Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol. 2006b;97:1602–6.PubMedCrossRef
46.
Janssen I, Mark AE. Elevated body mass index and mortality in the elderly. Obes Rev. 2007;8:41–59.PubMedCrossRef
47.
Elsayed EF, Samak MJ, Tighiouart H, Griffith JL, Kurth T, Salem DN, et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis. 2008;52:29–38.PubMedPubMedCentralCrossRef
48.
Chou CY, Lin CH, Lin CC, Huang CC, Liu CS, Lai SW. Association between waist-to-hip ratio and chronic kidney disease in the elderly. Int Med J. 2008;38:402–6.CrossRef
49.
Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, Levey AS, et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis. 2008b;52:49–57.PubMedPubMedCentralCrossRef
50.
Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;371:1927–35.PubMedCrossRef
51.
Monami M, Lamanna C, Balzi D, Bartalucci F, Melani C, Masotti G, et al. Metabolic syndrome and cardiovascular mortality in older type 2 patients:a longitudinal study. J Gerontol A Biol Sci Med Sci. 2008;63:646–9.PubMedCrossRef
52.
Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: The Hisayama Study. Am J Kidney Dis. 2006b;48:383–91.PubMedCrossRef
53.
Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006b;69:369–74.PubMedCrossRef
54.
Oniscu GC, Brown H, Forsythe JL. How old is old for transplantation? Am J Transplant. 2004;4:2067–74.PubMedCrossRef
55.
Remuzzi G, Cravedi P, Perna A, Dimitrov BD, Turturro M, Locatelli G, et al. Long-term outcome of renal transplantation from older donors. N Engl J Med. 2006;354:343–52.PubMedCrossRef
56.
Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet. 1992;340:807–10.PubMedCrossRef
57.
Gossmann J, Wilhelm A, Kachel HG, Jordan J, Sann U, Geiger Kramar W, et al. Long-term consequences of live kidney donation follow-up in 93% of living kidney donors in a single transplant center. Am J Transplant. 2005;5:2417–24.PubMedCrossRef
58.
Saran R, Marshall SM, Madsen R, Keavey P, Tapson JS. Long-term follow-up of kidney donors: a longitudinal study. Nephrol Dial Transplant. 1997;12:1615–21.PubMedCrossRef
59.
Fehrman-Ekholm I, Norden G, Lennerling A, Rizell M, Mjörnstedt L, Wramner L, et al. Incidence of end-stage renal disease among live kidney donors. Transplantation. 2006;82:1646–8.PubMedCrossRef
60.
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–9.PubMed
61.
Murray MD, Black PK, Kuzmik DD, Haag KM, Manatunga AK, Mullin MA, et al. Acute and chronic effects of nonsteroidal anti-inflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci. 1995;310:188–97.PubMedCrossRef
62.
Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Int Med. 2000;133:1–9.PubMedCrossRef
63.
Gooch K, Culleton BF, Manns BJ, ZHang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn BR. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120:280.e1–280.e7.PubMedCrossRef
1.
McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368–75.PubMedCrossRef
2.
Bader BD, Berger ED, Heede MB, Silberbaur I, Duda S, Risler T, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol. 2004;62:1–7.PubMedCrossRef
3.
Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93:C29–34.PubMedCrossRef
4.
Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328–34.PubMedCrossRef
5.
Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1,620 patients undergoing coronary angioplasty. Arch Int Med. 2002;162:329–36.CrossRef
6.
Cruz DN, Perazella MA, Bellomo R, Corradi V, de Cal M, Kuang D, et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis. 2006;48:361–71.PubMedCrossRef
7.
Frank H, Werner D, Lorusso V, Klinghammer L, Daniel WG, Kunzendorf U, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol. 2003;60:176–82.PubMedCrossRef
8.
Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T. Effects of oral adsorbent AST-120 on the progression of chronic renal failure:a randomized controlled study. Kidney Int. 1997;63 Suppl:S188–90.
9.
Shoji T, Wada A, Inoue K, Hayashi D, Tomida K, Furumatsu Y, et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract. 2007;105:99–107.CrossRef
10.
Takahashi N, Kawaguchi T, Suzuki T. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study. Int J Urol. 2005;12:7–11.PubMedCrossRef
11.
Sanaka T, Akizawa T, Koide K, Koshikawa S. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. Ther Apher Dial. 2004;8:232–40.PubMedCrossRef
12.
Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial. 2007;11:189–95.PubMedCrossRef
13.
Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis. 2006;47:565–77.PubMedCrossRef
14.
Yorioka N, Kiribayashi K, Naito T, Ogata S, Yokoyama Y, Kyuden Y, et al. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease. J Nephrol. 2008;21:213–20.PubMed
Metadata
Title
Evidence-based Practice Guideline for the Treatment of CKD
Publication date
01-12-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0237-8

Other articles of this Issue 6/2009

Clinical and Experimental Nephrology 6/2009 Go to the issue

Guidelines

List of Contributors

Case Report

Rapid deterioration of renal function in a patient with multiple myeloma associated with amyloid and light chain depositions

Acknowledgment

List of referees

Letter to the Editor

Recognition of downhill esophageal varices in hemodialysis patients requires a high index of clinical suspicion

Original Article

Reference serum creatinine levels determined by an enzymatic method in Japanese children: relationship to body length

Original Article

Histopathological spectrum of childhood nephrotic syndrome in Pakistan
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits